Strategic acquisitions Courtagen’s recent acquisition of Medicinal Genomics signals a growth strategy in epilepsy, mitochondrial disease, and autism sequencing. This presents a potential cross-sell opportunity to integrate broader genomic services into existing pediatric neurology workflows and expand reference data for improved diagnostics.

Pediatric focus The company emphasizes pediatric neurological disorders and family-centered testing with saliva-based samples, indicating a strong alignment with clinics serving children. This suggests targeted outreach to pediatric neurology practices, congenital centers, and children's hospitals seeking noninvasive, rapid genetic insights.

Fast turnaround Courtagen highlights rapid test results delivered in weeks, not months. Sales conversations can leverage this speed to position Courtagen as a preferable option for time-sensitive diagnostic decisions in epilepsy, mitochondrial disease, and autism management.

Financial accessibility The Courtagen Care Financial Assistance Plan offers significant flexibility on cost sharing, potentially broadening access for underserved families. This can be a differentiator in proposals to clinics serving publicly insured or low-income populations and can improve adoption rates.

Expert-driven reports Results are interpreted by senior geneticists and a Medical Director with extensive pediatric neurology experience. Emphasize the value of clinician-ready reports and expert interpretation as a service differentiator when engaging medical teams seeking actionable genetic insights for treatment decisions.